PRESS RELEASE published on 04/24/2026 at 07:00, 6 months 5 days ago BB Biotech Q1 2026: Share price outperformance, narrowing discount and active portfolio repositioning BB Biotech AG reports Q1 2026 results with share price outperformance, narrowing discount, and active portfolio repositioning. Eleven new investments made in biotech sector Share Price BB Biotech AG Investments Portfolio Repositioning Q1 2026
BRIEF published on 03/19/2026 at 17:45, 7 months 10 days ago L'assemblée générale annuelle de BB Biotech AG approuve les propositions et le dividende Stratégie D'investissement Assemblée Générale Annuelle Réélection Du Conseil D'administration Approbation Des Dividendes BB Biotech
BRIEF published on 03/19/2026 at 17:45, 7 months 10 days ago BB Biotech AG's AGM Approves Proposals and Dividend Annual General Meeting Investment Strategy Board Re-election Dividend Approval BB Biotech
PRESS RELEASE published on 03/19/2026 at 17:40, 7 months 10 days ago Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.25 per share Shareholders at BB Biotech AG's AGM approve CHF 2.25 dividend per share. Board proposals endorsed. Re-election of board members Shareholders Dividend AGM BB Biotech AG Board Proposals
BRIEF published on 02/20/2026 at 07:05, 8 months 9 days ago BB Biotech AG Releases 2025 Annual Report Dividend Proposal Biotechnology Sector Net Profit Increase BB Biotech 2025 Annual Report
BRIEF published on 02/20/2026 at 07:05, 8 months 9 days ago BB Biotech AG publie son rapport annuel 2025 Proposition De Dividende Augmentation Du Bénéfice Net BB Biotech Secteur De La Biotechnologie Rapport Annuel 2025
BRIEF published on 02/20/2026 at 07:05, 8 months 9 days ago BB Biotech's 2025 Annual Report Highlights Strong Financial Gains Annual Report Portfolio Value Shareholder Returns BB Biotech Financial Gains
BRIEF published on 02/20/2026 at 07:05, 8 months 9 days ago Le rapport annuel 2025 de BB Biotech met en lumière d'importants résultats financiers. Rapport Annuel BB Biotech Valeur Du Portefeuille Rendements Pour Les Actionnaires Gains Financiers
PRESS RELEASE published on 02/20/2026 at 07:00, 8 months 9 days ago EQS-Adhoc: BB Biotech AG publishes its 2025 annual report BB Biotech AG releases its 2025 annual report, reporting a strong performance with a +34.2% total return in CHF. The annual report includes detailed information on the biotechnology sector and the company's investments Financial Results Investment BB Biotech AG Biotechnology Sector 2025 Annual Report
PRESS RELEASE published on 02/20/2026 at 07:00, 8 months 9 days ago Annual Report 2025: BB Biotech delivers strong performance and portfolio value realization BB Biotech AG's Annual Report 2025 showcases strong performance and portfolio value realization. Shareholder returns, active capital management, and refined investment processes highlighted BB Biotech AG Portfolio Value Shareholder Returns Annual Report 2025 Investment Processes
Published on 10/29/2026 at 21:30, 33 minutes ago Shelfie Announces Amendments to Previously Announced Acquisition of Aspect
Published on 10/29/2026 at 18:30, 3 hours 33 minutes ago Kidoz Inc. Appoints Derek Sentner as Chief Revenue Officer
Published on 10/29/2026 at 16:05, 5 hours 58 minutes ago SouthGobi Announces Date of Special Meeting of Shareholders and The Record Date
Published on 10/29/2026 at 13:31, 8 hours 32 minutes ago First Breach Advances Ammunition and Drone Manufacturing Expansion as U.S. Reshoring Accelerates
Published on 10/29/2026 at 21:29, 34 minutes ago 2CRSi SA: Publication of the consolidated annual results and the 2025-2026 Annual Financial Report postponed to 30 October 2026
Published on 10/29/2026 at 21:29, 34 minutes ago 2CRSi SA: Report de la publication des résultats annuels consolidés et du Rapport Financier Annuel 2025-2026 au 30 octobre 2026
Published on 10/29/2026 at 21:20, 43 minutes ago 2CRSi SA: 2CRSi publie les conclusions de l'expert indépendant mandaté à la suite du rapport Grizzly Research et apporte des précisions sur plusieurs communications antérieures
Published on 10/29/2026 at 21:20, 43 minutes ago 2CRSi SA: 2CRSi publishes the conclusions of the independent expert appointed following the Grizzly Research report and provides clarifications on several previous communications
Published on 10/29/2026 at 20:13, 1 hour 50 minutes ago Interim individual financial statements of Sirma Group JSC for the period ending on September 30, 2026
Published on 10/29/2026 at 18:02, 4 hours 1 minute ago TF1 9M 2026 results - Consolidated financial statements and appendix
Published on 10/29/2026 at 18:02, 4 hours 1 minute ago Résultats TF1 9M 2026 - Comptes consolidés et annexes aux comptes
Published on 10/29/2026 at 18:00, 4 hours 3 minutes ago GUILLEMOT CORPORATION: THIRD-QUARTER 2026 TURNOVER / Successful new product launches and acceleration of international commercial partnerships
Published on 10/29/2026 at 18:00, 4 hours 3 minutes ago GUILLEMOT CORPORATION : CHIFFRE D’AFFAIRES TROISIEME TRIMESTRE 2026 / Succès des nouveaux lancements et accélération des partenariats commerciaux internationaux
